University of Pécs
1367

NeuroFlora

Microbiome modulation as a new therapeutic approach for autism and depression



CHALLENGE

Autism spectrum disorder and depression create a substantial disease burden. Alongside current treatments, new therapeutic approaches based on biological mechanisms are needed.

SOLUTION

NeuroFlora investigates targeted modulation of the gut microbiome through the gut–brain axis. It validates the biological effect, related neurobehavioural links and the potential for further development.

Gut–brain axis: central nervous system

Microbiome and gut–brain signalling



GUT–BRAIN AXIS

NeuroFlora is a targeted, patentable probiotic combination designed to modulate neural activity through the gut–brain axis and improve impaired social interaction. It is a side-effect-free, non-invasive therapy.

.

WHAT WE ARE LOOKING FOR

We are seeking USD 400K to fund regulatory approval and production of a food supplement prototype. From the current TRL 3 stage, the product could be market-ready within one year.

PROJECT TEAM

DR. ATTILA TÓTH
University of Pécs Medical School, Institute of Physiology
Project lead and scientific contact

DR. KITTI MINTÁL
University of Pécs, Assistant Professor

TRL 3
TECHNOLOGY READINESS

GLOBAL PATIENT POPULATION
62 M with autism
332 M with depression

COMMERCIALISATION PATH
Future licensing or technology transfer

TARGET INDICATIONS
Autism and depression

FAST MARKET ENTRY
FOOD SUPPLEMENT

PROJECT STAGE
Biological and neurobehavioural validation

NEXT STEP
Preclinical development

DIFFERENTIATOR
Links the gut microbiome with effects on the nervous system

Tradition & Innovation

Dancsházy Kinga
dancshazy.kinga@pte.hu